• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

接力式药物递释系统用于放大靶向信号和增强抗癌疗效。

Relay Drug Delivery for Amplifying Targeting Signal and Enhancing Anticancer Efficacy.

机构信息

Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, NC, 27695, USA.

Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.

出版信息

Adv Mater. 2017 Apr;29(13). doi: 10.1002/adma.201605803. Epub 2017 Feb 3.

DOI:10.1002/adma.201605803
PMID:28160337
Abstract

A "relay drug delivery" system based on two distinct modules, which is composed of a signal transmission nanocarrier A (NC ) that can specifically induce tumor blood vessel inflammation generation and an execution biomimetic nanocarrier B (NC ) that can accumulate at the tumor site by receiving the broadcasting signals generated by NC , is developed for amplifying active tumor targeting signal and enhancing antitumor therapy.

摘要

一种基于两个不同模块的“接力式药物传递”系统,由能特异性诱导肿瘤血管炎症产生的信号转导纳米载体 A(NC)和能通过接收 NC 产生的广播信号累积在肿瘤部位的仿生执行纳米载体 B(NC)组成,用于放大主动肿瘤靶向信号并增强抗肿瘤治疗效果。

相似文献

1
Relay Drug Delivery for Amplifying Targeting Signal and Enhancing Anticancer Efficacy.接力式药物递释系统用于放大靶向信号和增强抗癌疗效。
Adv Mater. 2017 Apr;29(13). doi: 10.1002/adma.201605803. Epub 2017 Feb 3.
2
CGKRK-modified nanoparticles for dual-targeting drug delivery to tumor cells and angiogenic blood vessels.载姜黄素介孔硅纳米粒双重靶向给药系统治疗肿瘤及血管新生
Biomaterials. 2013 Dec;34(37):9496-508. doi: 10.1016/j.biomaterials.2013.09.001. Epub 2013 Sep 17.
3
Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.Delta-like 配体 4 靶向纳米医学用于抗血管生成癌症治疗。
Biomaterials. 2015 Feb;42:161-71. doi: 10.1016/j.biomaterials.2014.11.039. Epub 2014 Dec 16.
4
Tyroservatide-TPGS-paclitaxel liposomes: Tyroservatide as a targeting ligand for improving breast cancer treatment.酪丝缬肽-聚乙二醇化维生素E琥珀酸酯-紫杉醇脂质体:酪丝缬肽作为一种用于改善乳腺癌治疗的靶向配体。
Nanomedicine. 2017 Apr;13(3):1105-1115. doi: 10.1016/j.nano.2016.10.017. Epub 2016 Nov 12.
5
In vitro and in vivo evaluation of APRPG-modified angiogenic vessel targeting micelles for anticancer therapy.用于抗癌治疗的APRPG修饰的血管生成靶向胶束的体外和体内评价
Int J Pharm. 2015;486(1-2):356-66. doi: 10.1016/j.ijpharm.2015.03.067. Epub 2015 Apr 1.
6
Tumor vascular-targeted co-delivery of anti-angiogenesis and chemotherapeutic agents by mesoporous silica nanoparticle-based drug delivery system for synergetic therapy of tumor.基于介孔二氧化硅纳米颗粒的药物递送系统实现肿瘤血管靶向共递送抗血管生成药物和化疗药物用于肿瘤协同治疗
Int J Nanomedicine. 2015 Dec 29;11:93-105. doi: 10.2147/IJN.S81156. eCollection 2016.
7
Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 2. In vivo distribution and tumor localization studies.聚环氧乙烷修饰的聚(β-氨基酯)纳米颗粒作为用于疏水性药物肿瘤靶向递送的pH敏感系统:第2部分。体内分布和肿瘤定位研究。
Pharm Res. 2005 Dec;22(12):2107-14. doi: 10.1007/s11095-005-8343-0. Epub 2005 Nov 3.
8
IF7-Conjugated Nanoparticles Target Annexin 1 of Tumor Vasculature against P-gp Mediated Multidrug Resistance.IF7共轭纳米颗粒靶向肿瘤血管的膜联蛋白1以对抗P-糖蛋白介导的多药耐药性。
Bioconjug Chem. 2015 Aug 19;26(8):1702-12. doi: 10.1021/acs.bioconjchem.5b00283. Epub 2015 Jun 26.
9
Somatostatin receptor-mediated specific delivery of paclitaxel prodrugs for efficient cancer therapy.生长抑素受体介导的紫杉醇前药特异性递送用于高效癌症治疗。
J Pharm Sci. 2015 Jun;104(6):2018-2028. doi: 10.1002/jps.24438. Epub 2015 Mar 27.
10
Prodrug-embedded angiogenic vessel-targeting nanoparticle: A positive feedback amplifier in hypoxia-induced chemo-photo therapy.载前药的血管生成靶向纳米颗粒:低氧诱导的化学生物治疗中的正反馈放大器。
Biomaterials. 2017 Nov;144:188-198. doi: 10.1016/j.biomaterials.2017.08.032. Epub 2017 Aug 18.

引用本文的文献

1
Inhibition of growth of hepatocellular carcinoma by co-delivery of anti-PD-1 antibody and sorafenib using biomimetic nano-platelets.仿生纳米血小板共递送抗 PD-1 抗体和索拉非尼抑制肝癌生长。
BMC Cancer. 2024 Feb 26;24(1):273. doi: 10.1186/s12885-024-12006-1.
2
Active recruitment of anti-PD-1-conjugated platelets through tumor-selective thrombosis for enhanced anticancer immunotherapy.通过肿瘤选择性血栓形成主动募集抗 PD-1 偶联血小板以增强抗癌免疫治疗。
Sci Adv. 2023 Mar 29;9(13):eadf6854. doi: 10.1126/sciadv.adf6854.
3
Biomimetic cell-derived nanocarriers in cancer research.
仿生细胞衍生的纳米载体在癌症研究中的应用。
J Nanobiotechnology. 2022 Dec 22;20(1):538. doi: 10.1186/s12951-022-01748-4.
4
Platelets and platelet extracellular vesicles in drug delivery therapy: A review of the current status and future prospects.药物递送治疗中的血小板和血小板细胞外囊泡:现状与未来展望综述
Front Pharmacol. 2022 Oct 18;13:1026386. doi: 10.3389/fphar.2022.1026386. eCollection 2022.
5
Biomedical polymers: synthesis, properties, and applications.生物医学聚合物:合成、性质及应用
Sci China Chem. 2022;65(6):1010-1075. doi: 10.1007/s11426-022-1243-5. Epub 2022 Apr 24.
6
Overcoming Vascular Barriers to Improve the Theranostic Outcomes of Nanomedicines.克服血管屏障以提高纳米药物的治疗效果。
Adv Sci (Weinh). 2022 May;9(13):e2103148. doi: 10.1002/advs.202103148. Epub 2022 Mar 4.
7
Research Progress on Cell Membrane-Coated Biomimetic Delivery Systems.细胞膜包覆仿生递送系统的研究进展
Front Bioeng Biotechnol. 2021 Nov 16;9:772522. doi: 10.3389/fbioe.2021.772522. eCollection 2021.
8
Cell membrane-covered nanoparticles as biomaterials.细胞膜包覆的纳米颗粒作为生物材料。
Natl Sci Rev. 2019 May;6(3):551-561. doi: 10.1093/nsr/nwz037. Epub 2019 Mar 14.
9
A Sequential Dual-Model Strategy Based on Photoactivatable Metallopolymer for On-Demand Release of Photosensitizers and Anticancer Drugs.一种基于光可激活金属聚合物的顺序双模型策略,用于按需释放光敏剂和抗癌药物。
Adv Sci (Weinh). 2021 Dec;8(23):e2103334. doi: 10.1002/advs.202103334. Epub 2021 Oct 18.
10
Bioactive nanotherapeutic trends to combat triple negative breast cancer.用于对抗三阴性乳腺癌的生物活性纳米治疗趋势。
Bioact Mater. 2021 Mar 13;6(10):3269-3287. doi: 10.1016/j.bioactmat.2021.02.037. eCollection 2021 Oct.